Tag Archives: Pharmaceutical industry

18Aug/23

Heart Failure start-up, Acorai, embarks on the next vital stage towards regulatory approval

Reasearch, , , , , , , , ,

Today, Acorai, a start-up medical device manufacturer from Sweden, has announced the initiation of a global clinical trial with the enrollment of its first patient in London, UK. Acorai was designated as a breakthrough device by the US FDA in August 2023 and they aim to submit their heart monitor for regulatory approval to the FDA and CE-marking in 2024. Continue reading

13Mar/23

Pfizer Invests $43 Billion to Battle Cancer

Reasearch, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,
Pfizer to acquire Seagen for $229 per Seagen share in cash, for a total enterprise value of approximately $43 billion
Proposed combination enhances Pfizer’s position as a leading company in Oncology
Seagen’s medicines, late-stage development programs and pioneering expertise in Antibody-Drug Conjugates (ADCs) strongly complement Pfizer’s Oncology portfolio
Seagen expected to contribute more than $10 billion in risk-adjusted revenues in 2030
Pfizer and Seagen to hold analyst and investor call at 8 a.m. EDT today

NEW YORK & BOTHELL, Wash.–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of $43 billion. The Boards of Directors of both companies have unanimously approved the transaction. Continue reading →